Research
Hormonal
Incretin therapies reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with T2DM and/or established cardiovascular disease, independent of glycemic control.
If you have heart disease or high risk, these drugs offer significant protection against heart attacks and death, separate from weight loss. This benefit is a key factor in their clinical value and reimbursement decisions.
GoodSupportsHIGH confidence
In SUSTAIN-6, semaglutide reduced HbA1c and lowered major adverse cardiovascular events (MACE) by 26% in T2DM patients at high cardiovascular risk... tirzepatide use was associated with approximately 24% lower hazard of composite MACEs and a 42% lower hazard of all-cause mortality compared to semaglutide
Why this rating
Supported by large RCTs (SUSTAIN-6, SELECT, SURPASS-CVOT) and real-world cohort studies.
Source
Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications
Luke Awadalla et al. · Canadian Journal of Physiology and Pharmacology · 2026
DOI 10.1139/cjpp-2025-0248
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) are clinically effective for glycemic control and significant weight loss, with tirzepatide demonstrating superior magnitude of weight loss compared to semaglutide in head-to-head trials.Good
- Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →